🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Shares

Walgreens Boots profit beats on higher prescription sales

Published 09/07/2015, 12:22
Updated 09/07/2015, 12:25
© Reuters.  Walgreens Boots profit beats on higher prescription sales
AVP
-
WBA
-

(Reuters) - Drugstore chain Walgreens Boots Alliance Inc (O:WBA), formed by Walgreens' takeover of Europe's Alliance Boots in December, reported a better-than-expected quarterly profit, helped by higher prescription sales and lower costs.

Walgreens Boots Alliance also bought Avon Products Inc's (N:AVP) U.K.-based Liz Earle skincare business for 140 million pounds ($215.32 million).

Net income attributable to Walgreens Boots rose to $1.30 billion, or $1.18 per share, in the third quarter ended May 31, from $714 million, or 74 cents per share, a year earlier.

Excluding items, the company earned $1.02 per share, beating the average analysts estimate of 87 cents, according to Thomson Reuters I/B/E/S.

Net sales rose 48 percent to $28.80 billion, driven by the merger with Alliance Boots.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.